Home
News
Create
Screeners
Insights
Coral Laboratories
426.
95
-6.05
(-1.40%)
Market Cap
₹152.44 Cr
PE Ratio
11.05
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.40%
1M
+6.74%
6M
-13.22%
1Y
-38.58%
5Y
+14.60%
View Company Insights
Latest news about Coral Laboratories
Coral Laboratories Appoints Mr. Diwakar Unnikrishna Menon as Company Secretary and Compliance Officer
1 day ago
Yesterday
Coral Laboratories Limited has appointed Mr. Diwakar Unnikrishna Menon (ACS: 8791) as Company Secretary and Compliance Officer effective April 30, 2026. The appointment was approved by the Board of Directors on April 23, 2026, based on the Nomination and Remuneration Committee's recommendation. Mr. Menon brings over 33 years of experience in compliance, legal, and industrial safety, having worked with reputed organizations like Godrej group and L&T group. The company confirmed he is not debarred by any regulatory authority and is not related to any directors, key managerial personnel, or promoters.
Coral Laboratories Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026
9 days ago
Coral Laboratories Issues Postal Ballot Notice for Independent Director Re-appointment
Apr 06, 2026
Coral Laboratories Completes Capacity Expansion at Dehradun Plant, Commences Commercial Operations
Mar 24, 2026
Coral Laboratories Q3FY26 Results: Net Profit Declines 54.84% to ₹277.55 Lakhs
Feb 13, 2026
More news about Coral Laboratories
30
Dec 25
Coral Laboratories Company Secretary and Compliance Officer Resigns Effective January 31, 2026
Coral Laboratories has announced the resignation of Mrs. Dhwani Desai from her position as Company Secretary and Compliance Officer, effective January 31, 2026. She is stepping down to pursue another career opportunity, and the Board has accepted her resignation. Following her departure, Mrs. Desai will also cease to be Key Managerial Personnel of the company. The pharmaceutical company has complied with SEBI disclosure requirements by informing BSE Limited of this personnel change.
13
Oct 25
Coral Laboratories Approves ₹30 Crore Capacity Expansion at Dehradun Plant
Coral Laboratories Limited has approved a capacity expansion project at its Dehradun plant, aiming to triple ointment manufacturing capacity from 180,000 kgs to 540,000 kgs. The ₹30 crore investment, to be financed through bank overdraft and internal accruals, is expected to complete in 6 months. The expansion addresses growing demand in domestic and international markets, with current capacity utilization at 80%. The company aims to meet captive demand, support sales growth, and facilitate overall business expansion.
Coral Laboratories
426.
95
-
6.
05
(-
1.
40
%)
1 Year Returns:
-38.58%
Industry Peers
Sun Pharmaceutical
1,620.40
(-
3.
55
%)
Divis Laboratories
6,361.50
(-
0.
27
%)
Torrent Pharmaceuticals
4,117.20
(-
0.
72
%)
Dr Reddys Laboratories
1,317.10
(-
1.
04
%)
Lupin
2,296.10
(-
1.
93
%)
Cipla
1,295.00
(-
0.
83
%)
Mankind Pharma
2,267.40
(-
1.
11
%)
Zydus Life Science
927.40
(-
2.
00
%)
Aurobindo Pharma
1,413.80
(-
1.
50
%)
Glenmark Pharmaceuticals
2,299.50
(-
1.
52
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO